Avalo Therapeutics Inc. (AVTX)
5.85
-0.74 (-11.23%)
At close: Apr 04, 2025, 3:59 PM
6.09
4.02%
After-hours: Apr 04, 2025, 05:45 PM EDT
-11.23% (1D)
| Bid | 5.85 |
| Market Cap | 62.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -20.91 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | -1.71 |
| Analyst | Buy |
| Ask | 6.59 |
| Volume | 46,179 |
| Avg. Volume (20D) | 74,362 |
| Open | 6.46 |
| Previous Close | 6.59 |
| Day's Range | 5.56 - 6.50 |
| 52-Week Range | 5.56 - 18.79 |
| Beta | 0.72 |
About AVTX
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 14, 2015
Employees 23
Stock Exchange NASDAQ
Ticker Symbol AVTX
Website https://www.avalotx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for AVTX stock is "Buy." The 12-month stock price forecast is $35.5, which is an increase of 506.34% from the latest price.
Stock Forecasts1 week ago
+11.93%
Avalo Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
7 months ago
+8.88%
Avalo Therapeutics shares are trading higher after BVF Partners disclosed in a 13G filing that it reported a 9.99% stake in the company.
